medigraphic.com
ISSN 1561-3186 (Electronic)

2021, Number 3

Next >>

Rev Acta Médica 2021; 22 (3)

Recurrences of non-melanoma skin cancer treated with conventional surgery

Castro TAC, García GR, Florez SV, Salazar SM, Labori QP

Language: Spanish
References: 26
Page:
PDF size: 109.95 Kb.


ABSTRACT

Introduction: Non-melanoma skin cancer constitutes 50% of all types of cancer and it includes Basal Cell Carcinoma and Squamous Cell Carcinoma. Conventional surgery is still the most used technique in most cases. It offers the advantages of histological control, rapid healing and optimal cosmetic results, if the general conditions of the patient allow so. Although, a significant number of patients have tumor recurrence, especially in the first 5 years.
Objective: To characterize recurrences in patients operated on for non-melanoma skin cancer by conventional surgery at “Hermanos Ameijeiras” Clinical Surgical Hospital from 2014 to April 2020.
Methods: This is a descriptive, prospective and longitudinal study. From the universe made up of patients operated on for non-melanoma skin cancer by conventional surgery, a sample was chosen by the consecutive inclusion of 47 patients who had tumor recurrences confirmed by histology and who consented so. The data obtained from medical records and surveys were recorded in a form including variables such as time of appearance of recurrences, type and location of the tumor, histological subtype.
Results: The appearance of recurrences occurred before 1 year, and from 1 to 2 years after the operation in 21.3%, respectively. Basal Cell Carcinoma of the Sclerodermiform histological subtype was more frequent, and Squamous Cell Cancer, a Grade 2 histological subtype, moderately differentiated. The most frequent location was on the face (57.4%).
Conclusions: Non-melanoma skin cancer in cases with recurrences was categorized by lesions mainly in exposed areas, it occurred in a negligible period, with predominance of Basal Cell Carcinoma. Particularly the Sclerodermiform type was the one that, histologically, most affected patients operated on for tumors of this nature.


REFERENCES

  1. National Comprehensive Cancer Network. Clinical Practice Guidelines inoncology: guidelines index basal cell and squamous cell TOC staging. NCCN. 2010[acceso:14/02/2021]. Disponible en:https://www.google.com/search?q=National+Comprehensive+Cancer+Network.+Clinical+Practice+Guidelines+in+oncology%3A+guidelines+index+basal+cell+and+squamous+cell+TOC+staging.+Washington%3A+NCCN%3B+2010.&oq=National+Comprehensive+Cancer+Network.+Clinical+Practice+Guidelines+in+oncology%3A+guidelines+index+basal+cell+and+squamous+cell+TOC+staging.+Washington%3A+NCCN%3B+2010.&aqs=chrome..69i57.8873j0j4&client=ms-androidhuawei&sourceid=chrome-mobile&ie=UTF-8

  2. Leibovitch I, Huilgol S, Selva D, Richards S, Paver R. Basal cellcarcinoma treatedwith Mohs surgery in Australia I. Experienceover 10 years. J Am Acad Dermatol.2011[acceso:14/02/2021];53:458-63. Disponible en:https://pubmed.ncbi.nlm.nih.gov/16112353/

  3. Chen T, Bertentha DL, Sahay A. Predictors of skin-relatedquality of life aftertreatment of cutaneous basal cellcarcinoma and squamous cell carcinoma. ArchDermatol. 2010[acceso.12/01/2021];143:1386-92. Disponible en:https://pubmed.ncbi.nlm.nih.gov/18025362/

  4. Roewert-Huber J, Lange-Asschenfeldt B, Stockfleth E. Epidemiology andaetiology of basal cell carcinoma. Br J Dermatol.2012[acceso:12/01/2021];157:47-51. Disponible en:https://pubmed.ncbi.nlm.nih.gov/18067632/

  5. Christenson L, Borrowman T, Vachon C. Incidence of basal celland squamouscell carcinomas in a population younger than 40 years. JAMA.2013[acceso:12/01/2021];294:681-90. Disponible en:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5535132/

  6. Martorell Calatayud A, Sanmartín Jiménez O, Cruz Mojarrieta J, Guillén BaronaC. Carcinoma epidermoide cutáneo: definiendo la variante de alto riesgo. ActasDermosifiliogr. 2013[acceso:12/01/2021];104:367-79. Disponible en:https://www.actasdermo.org/es-carcinoma-epidermoide-cutaneo-definiendovariante-articulo-S0001731012001974

  7. Bordelois-Abdo JA, Lagos-Ordoñez KJ, López-Mateus M. Cáncer de piel nomelanoma en adultos mayores de hogares de ancianos, Guantánamo 2017-2019.Rev Inf Cient. 2020[acceso:14/04/2021];99(3):[aprox.8p.]. Disponible en:http://www.revinfcientifica.sld.cu/index.php/ric/article/view/2926

  8. Sánchez F. Consideraciones sobre la capa de ozono y su relación con el cáncerde piel. Rev Méd Chile 2015[acceso:12/01/2021];134:1185-90. Disponible en:https://www.scielo.cl/scielo.php?pid=S0034-98872006000900015&script=sci_arttext

  9. Telfer NR, Colver GB, Morton CA. Guidelines for the management of basal cellcarcinoma. Br J Dermatol. 2013[acceso:12/01/2021];159:35-48. Disponible en:https://pubmed.ncbi.nlm.nih.gov/10583044/

  10. Stulberg DL, Crandell B, Fawcett RS. Diagnosis and treatment of basal cell andsquamous cell carcinomas. Am FamPhysician. 2014[acceso:12/01/2021];70:1481-8. Disponible en: https://pubmed.ncbi.nlm.nih.gov/22962928/

  11. Aguayo Y, Ríos B, P. Jaén O. Tratamiento quirúrgico vs. no quirúrgico en elCarcinoma Basocelular. Actas Dermosifiliogr.2010[acceso:12/01/2021];101(8):683–692. Disponible en:https://www.actasdermo.org/es-tratamiento-quirurgico-vs-no-quirurgicoarticulo-S0001731010002796

  12. Brodland DG, Zitelli JA. Surgical margins for excision of primary cutaneous cellcarcinoma. J Am Acad Dermatol. 2015[acceso:12/01/2021];27:241–8. Disponibleen: https://pubmed.ncbi.nlm.nih.gov/1430364/

  13. Chren MM, Linos E, Torres JS, Stuart SE, Rupa Parvataneni MS, Boscardin WJ.Tumor recurrences, five years after treatment ofcutaneous basal cell carcinomaand squamous cell carcinoma. J Invest Dermatol.2013[acceso:12/01/2021];133:1188-96. Disponible en:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3711403/

  14. Rapini RP. Comparison of methods for checking surgical margins.J Am AcadDermatol. 2014[acceso:12/01/2021];23:288-94. Disponible en:https://pubmed.ncbi.nlm.nih.gov/2212126/

  15. Schwartz R. Cáncer de piel no melanoma en cabeza y cuello. Revista MédicaClínica Las Condes. 2018;29(4):[aprox.9p.]. DOI:https://doi.org/10.1016/j.rmclc.2018.06.007

  16. Visón MA, Dunkin J, Suvarna S, Griffiths RW. Do plastic surgeons resect basalcell carcinomas too widely? A prospective study comparing surgical and histologicalmargins. Br J Plastic Surg. 2016[acceso:15/02/2019]55:293-7. Disponible enhttps://pubmed.ncbi.nlm.nih.gov/12160534/

  17. Kumar P, Waston S, Brian A, Davenport P, McWilliam LJ, Banerjee S, et al.Incomplete excision of basal cell carcinoma: a prospective multicentre audit.British J Plastic Surg. 2017[acceso:14/04/2021];55:616-22. Disponible en:https://pubmed.ncbi.nlm.nih.gov/12550113/

  18. Geisse J, Caro I, Lindhom J, Golitz L, Stampone P, Owens M. Imiquimod 5%cream for the treatment of superficial basal cell carcinoma: Results from twophases III, randomized, vehiclecontrolled studies. J Am Acad Dermatol.2017[acceso:15/02/2019];50:722-33. Disponible en:https://pubmed.ncbi.nlm.nih.gov/15097956/

  19. Domínguez-Cherit J, Rodríguez-Gutiérrez G, Narváez Rosales V, Toussaint CaireS, Fonte Avalos V. Características del carcinoma epidermoide cutáneo y riesgo parael desarrollo de recidivas con cirugía convencional y cirugía con transoperatoriotardío. Revista Cirugía-Cirujanos. 2016[acceso:12/01/2021];85(6):499-503.Disponible en: https://www.elsevier.es/es-revista-cirugia-cirujanos-139-articulocaracteristicas-del-carcinoma-epidermoide-cutaneo-S0009741116301347

  20. Sialer-Vildózola MC, Navarrete-Mejia PJ. Características epidemiológicas delcáncer de piel no melanoma en militares, 2015-2016: Perú. Rev. argent. dermatol.2017[acceso:14/04/2021];98(4):1-10. Disponible en:http://www.scielo.org.ar/scielo.php?script=sci_arttext&pid=S1851-300X2017000400008&lng=es

  21. Paola Castañeda G, Eljure Téllez J. El cáncer de piel, un problema actual.Revista de la Facultad de Medicina de la UNAM. 2016[acceso:15/02/2019];59(2).Disponible en: https://www.medigraphic.com/pdfs/facmed/un_2016/un162b.pdf

  22. Urrego-Rivera FL, Faura-Berrugab C. Diagnóstico diferencial del CarcinomaBasocelular pigmentado. Rev Clin Med Fam. 2015[acceso:21/06/2019];8(1):166-77. Disponible en: https://www.scielo.isciii.es/pdf/albacete/v8n2/paciente.pdf

  23. Victoria HO. Caracterización clínica e histopatológica del cáncer cutáneo nomelanoma. Rev AMC. 2010[acceso:21/06/2018];14(3). Disponible en:http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S102502552010000300006

  24. Sánchez Vanegas, G. Cáncer de piel no melanoma: riesgos e itinerarios. Revistade Medicina. 2016[acceso:14/04/2021];38(2):[aprox.4p.] Disponible en:http://revistamedicina.net/ojsanm/index.php/Medicina/article/view/113-9a

  25. Peña Pérez OR, Alvarez Yabor Vd, Yabor Palomo AM, Morales Fontaine A,Ricardo Peña A. Estudio de cinco años en pacientes de Las Tunas con cáncercutáneo no melanoma. Revista Electrónica Dr. Zoilo E. Marinello Vidaurreta.2015[acceso:14/04/2021];41(1). Disponible en:http://www.revzoilomarinello.sld.cu/index.php/zmv/article/view/520

  26. Manfredi M, Vescovi P, Bonanini M, Porter S. Nevoid basal cell carcinomasyndrome: a review of the literature. Int J Oral Maxillofac Surg.2017[acceso:01/01/2021];33:117-24. Disponible en:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3453702/




2020     |     www.medigraphic.com